Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-857-9 | CAS number: 12037-29-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 January 2018 to 16 August 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
- Objective of study:
- toxicokinetics
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Note for Guidance on Toxicokinetics: the Assessment of Systemic Exposure in Toxicity Studies, PAB/PCD Notification No. 443
- Version / remarks:
- July 2, 1996
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Analysis was conducted at IDEA Consultants, Inc. under non-GLP condition.
Test material
- Reference substance name:
- Praseodymium(III,IV) oxide
- EC Number:
- 234-857-9
- EC Name:
- Praseodymium(III,IV) oxide
- Cas Number:
- 12037-29-5
- Molecular formula:
- O11Pr6
- IUPAC Name:
- tetrakis(λ⁴-praseodymium(4+)) dipraseodymium(3+) undecaoxidandiide
- Test material form:
- solid: particulate/powder
- Details on test material:
- - Storage conditions: Under room temperature (1 to 30 °C) in the dark and sealed container
- Actual storage temperature and storage period: - 18.7 to 22.7 °C - 16 October 2017 to 30 January 2018 (from receipt to the day of final preparation of dosing formulations)
Constituent 1
- Specific details on test material used for the study:
- Lot number: REACH 0000383394
- Radiolabelling:
- no
Test animals
- Species:
- mouse
- Strain:
- other: CD2F1/Slc [SPF]
- Details on species / strain selection:
- CD2F1/Slc mice are used as the non-transgenic animals of same rodent strain of in vivo gene mutation assay. It is assumed that the observed toxicity profile in the wild-type animals reflect that observed in the transgenic animals.
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Japan SLC, Inc.
- Age at study initiation: 9 weeks of age
- Weight at study initiation: 23.3 to 29.9 g
- Housing: All animals were housed in a barrier system room of No. 7-117 [positive pressure] (W 4.8 × D 10.3 × H 2.6 m). One to three animals were housed in a plastic cage (W 18.2 × D 26.0 × H 12.8 cm) with bedding (ALPHA-dri™; lot No. 01117; Shepherd Specialty Papers). The analytical result of the bedding for contaminants was received from the manufacturer and it was confirmed that the levels of contaminants were within the acceptable limits of the Japan Experimental Animal Feed Association. The animal cages, the bedding and the feeders were replaced on Day 1 and once a week thereafter. The water bottles were replaced once every 2 or 3 days.
- Diet: ad libitum access to pellet diet
- Water: ad libitum
- Acclimation period: Upon arrival, each animal was monitored for general condition and body weight gains. During the quarantine and acclimation period (Day -7 to Day -1), the animals were observed once or more a day. The body weight of each animal was measured on the day of receipt and at the end of the quarantine and acclimation period. None of the animals showed abnormalities in their general condition or body weight gain.
ENVIRONMENTAL CONDITIONS
- Temperature: 22.6 -23.5 °C
- Humidity: 48 – 60 %
- Air changes:12 times or more/hour
- Photoperiod: 12 hours (lights on: 7:00, lights off: 19:00)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- methylcellulose
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- Preparation of vehicle (0.5 w/v % MC): An aqueous solution of methylcellulose 400 at 0.5 % (w/v) was used for the negative control. Methylcellulose 400 (2 or 4 g) was accurately weighed and transferred into a toppered volumetric cylinder. A small volume of warmed (approximately 80°C) water for injection was repeatedly added to dissolve it. After this solution was cooled to room temperature, it was adjusted to 400 or 800 mL with water for injection to make 0.5 w/v % solution. The prepared vehicle was stored in a refrigerator and was used within 14 days after preparation.
- Preparation of test material formulations:
Test material formulation (100 mg/mL): 10.0 g of the test material was weighed and transferred to a stoppered measuring cylinder and mixed with a small volume of vehicle. It was diluted to 100 mL with vehicle to prepare a 100 mg/mL formulation. The formulation was fully mixed by manual inversion and then stirred by magnetic stirrer until visibly homogeneous.
- Dispensing and storage of the test material formulations: Each test material formulation was divided into 8 portions (including 1 portion as reserve) for each administration under continuous stirring using a magnetic stirrer and stored in tight and light-resistant containers in a refrigerator (acceptable temperature range: 1 to 9 °C) until use. The actual temperature range was 3.6 to 7.6 °C during the storage period. The stored formulations were fully mixed by manual inversion and then stirred by a magnetic stirrer at least 30 minutes before use.
- Stability of the test material formulations: Within a concentration range of 10.0 to 200 mg/mL, the test material was confirmed to be stable and homogeneous in 0.5 % (w/v) methylcellulose 400 after storage for at least 8 days at ambient laboratory temperature and 2 to 8°C in the dark in the study [Validation of Methodologies for the Analysis of Praseodymium Oxide in Oral (Gavage) Dosing Formulations[1]]. And also, it was confirmed under non-GLP condition that the 10.0 and 100 mg/mL dosing formulations stored at 0 to 10°C were stable and homogeneous in 0.5 w/v % MC for at least 15 days.
- Analysis of test material formulations: The concentration of the test material formulation (100 mg/mL) prepared by the same method was confirmed in the previous study titled “Praseodymium (III, IV) oxide: Transgenic Mice (Muta™Mouse) Gene Mutation Assay [BSRC’s Exp. No. H927 (704-003)]”, and the results showed that the test material formulation had been appropriately prepared. - Duration and frequency of treatment / exposure:
- The test material was administered to animals once daily for 14 consecutive days by using a disposable syringe with a Teflon sonde. The test material was administered from Day 8 to Day 21 alongside the gene mutation assay titled “Praseodymium (III, IV) oxide: Transgenic Mice (Muta™Mouse) Gene Mutation Assay.
Doses / concentrations
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose / concentration:
- 37 males
- Control animals:
- yes, concurrent no treatment
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: In the acute oral toxicity study male and female Sprague-Dawley (SD) rats treated with 2000 mg/kg of test material in 0.5 % (w/v) methylcellulose, no clinical signs and no changes of the body weight gain of the animals were observed. Combined repeated dose and reproduction/developmental screening study using SD rats revealed that the no observed adverse effect level (NOAEL) was 1000 mg/kg/day groups. Toxicity to mice was not observed, in the dose range-finding study [BSRC’s Exp. No. H926 (704-002)] in CD2F1/Slc mice treated with 100, 300 or 1000 mg/kg/day of test material in 0.5 w/v % MC. Therefore, a dosage of 1000 mg/kg/day was selected as the dose in the present study.
- Rationale for animal assignment: Animals were assigned to groups based on their body weights on Day -1 using LATOX-F/V5 computer system package. The weight range of animals was within the mean weight ±20 %. - Details on dosing and sampling:
- DOSING ADMINISTRATION
- Before administration, the test material formulations were shaken by hand. Then, the individual dosing volumes of test material formulations were taken under continuous stirring using a magnetic stirrer for at least 30 minutes before use. The test material was administered orally by gavage according to the test guideline. The test material was administered to animals once daily for 14 consecutive days by using a disposable syringe with a Teflon sonde. The test material was administered from Day 8 to Day 21 alongside the gene mutation assay titled “Praseodymium (III, IV) oxide: Transgenic Mice (Muta™Mouse) Gene Mutation Assay.
- The dosing volume (mL) was set at 10 mL per kg body weight. The individual dosing volume (mL) was calculated on the basis of the most recent individual body weight measured.
OBSERVATIONS
- Observation of clinical signs was performed daily.
- Individual body weights of the animals in the negative control group and the test material-treated group were measured on Day -7 (day of receipt), Day -1 (day of assignment to groups), Day 7 and Day 14 (just before sampling).
TOXICOKINETIC ANALYSIS
- Analyte: Praseodymium (element) in mouse plasma
- Method of TK Sampling:
Method of blood collection: Blood was sampled from the abdominal aorta under isoflurane anaesthesia. Disposable syringes coated with heparin sodium and 23G or 25G needles were used for the blood sampling. The blood samples were transferred to polypropylene tubes and placed immediately on ice. Sampling volume: approximately 1.0 mL
Anticoagulant: Heparin sodium (1000 U/mL), 5 μL
Collection post-processing: 1) 13600 × g for 1 minute at 4 °C. 2) The upper layer (plasma) was collected, which was assumed to be a TK sample.
- Sampling point: Blood was sampled before dosing, at 1, 2, 4, and 8 hours after dosing on Day 1, and also, 1, 2, 4, and 8 hours after dosing on Day 14.
- Spare animals: Spare animals were prepared for blood collection on Day 1 and Day 14. The animals with 33 to 37 of last two digits of animal ID No. were used. When the following criteria were met, the spare animals were planned to be used, but actually were not used.
Criterion for using of spare animals:
- the blood from 4 animals was secured in each point
- moribund or dead animals were occurred
- the time of blood collecting was deviated from permissible range
- the volume of blood collected from one animal was less than 0.5 mL
- Permissible range for time of blood collecting: At 1, 2 and 4 hours after dosing: ±10 % of the scheduled time of blood collecting Before dosing and 8 hours after dosing: ±5 % of the scheduled time of blood collecting
- Storage of TK samples: Each plasma sample was identified with a label showing the experiment No., animal ID No., date and time of blood collection, and stored in a deep freezer for TK samples (acceptable range: -90 to -60 °C; actual value: -81.4 to -74.2 °C) until sending to IDEA Consultants, Inc. Since the results of the gene mutation assay titled “Praseodymium (III, IV) oxide: Transgenic Mice (Muta™Mouse) Gene Mutation Assay [BSRC’s Exp. No. H927 (704-003)]” were negative, the TK measurement was conducted using these samples according to the sponsor’s instructions.
- Handling of spare animals: All spare animals were euthanatized by CO2 inhalation after blood collection on Day 14.
- Sampling of blank plasma:
Animals: For collecting blank plasma, 23 male mice (CD2F1/Slc, 9 weeks of age) were purchased from Japan SLC, Inc.
- Method of blank plasma sampling: Blank plasma was collected according to the method described previously. On the day of animal arrival. Plasma from 3 animals was collected individually. Plasma from other animals was pooled. The blank plasma was stored in the same deep freezer as the TK samples.
Results and discussion
Toxicokinetic / pharmacokinetic studies
Toxicokinetic parametersopen allclose all
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- Tmax: 4 hours
- Remarks:
- [First dose]
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- Cmax: 1.12 ng/mL
- Remarks:
- [First dose]
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- AUC: (0-8h) 6.45 ng.h/mL
- Remarks:
- [First dose]
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- Tmax: 1 hours
- Remarks:
- [Final dose (Day 14)]
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- Cmax: 0.94 ng/mL
- Remarks:
- [Final dose (Day 14)]
- Key result
- Test no.:
- #1
- Toxicokinetic parameters:
- AUC: (0-8h) 4.16 ng.h/mL
- Remarks:
- [Final dose (Day 14)]
Metabolite characterisation studies
- Metabolites identified:
- not specified
Any other information on results incl. tables
- TK measurement:
First dose: The Tmax value for Praseodymium (element) at the dose of 1000 mg/kg was 4 hours and the Cmax value was 1.12 ng/mL. The AUC0-8h value was 6.45 ng·h/mL.
Final dose (Day 14): The Tmax value for Praseodymium (element) at the dose of 1000 mg/kg was 1 hour and the Cmax value was 0.94 ng/mL. The AUC0-8h value was 4.16 ng·h/mL.
- Body weight and general conditions: No apparent suppression of the body weight gain nor noteworthy symptom was observed.
Table 1: Concentration of Praseodymium in the mouse plasma
Sampling Point |
Dose (mg/kg/day) |
Concentration of Praseodymium in the plasma (ng/mL) (Mean ± S.D.) |
Cmax (ng/mL) |
Tmax (h) |
AUC0-8h (ng.h/mL) |
||||
Pre |
1 h |
2 h |
4 h |
8 h |
|||||
First dose |
Non-treatment |
BLQ |
- |
- |
- |
- |
- |
- |
- |
Vehicle |
- |
BLQ |
BLQ |
BLQ |
BLQ |
BLQ |
- |
- |
|
Test material 1000 |
- |
0.41 ± 0.32 |
0.49 ± 0.88 |
1.12 ± 0.53 |
0.97 ± 0.57 |
1.12 |
4 |
6.45 |
|
Final dose (at 14 days) |
Vehicle |
- |
BLQ |
BLQ |
BLQ |
BLQ |
BLQ |
- |
- |
Test material 1000 |
- |
0.94 ± 0.59 |
0.59 ± 0.26 |
0.57 ± 0.25 |
0.31 ± 0.36 |
0.94 |
1 |
4.16 |
BLQ (below limit of quantification) : <0.14 ng/mL
BLQ is assigned zero for the calculation of the mean, S.D., Cmax and AUC0-8h.
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this study, the results indicated that when Praseodymium (III, IV) oxide was administered to mice at the concentration of 1000 mg/kg/day, a fraction of Praseodymium was absorbed in the plasma.
- Executive summary:
In order to assess systemic exposure, the test material was administered at 1000 mg/kg/day to CD2F1/Slc male mice daily for 14 days, and Praseodymium (element) in plasma at the first dose (D1) and the final dose (D14) were determined using ICP-MS. For TK analysis, blood samples were collected before dosing, at 1, 2, 4, and 8 hours after first dose, and also, 1, 2, 4, and 8 hours after final dose (at 14 days). The TK measurement was conducted at IDEA Consultants, Inc. under non-GLP condition.
At the first dose sampling point the Cmax was 1.12 ng/mL, the Tmax was 4 hours and the AUC0-8h was 6.45 ng.h/mL. At the final dose (14 days) sampling point the Cmax was 0.94 ng/mL, the Tmax was 1 hour and the AUC0-8h was 4.16 ng.h/mL.
The AUC0-8h value for Praseodymium (element) at the final dose was 0.64-fold compared to that at the first dose, and the Cmax value was also lower than that at the first dose. In the negative control group, the concentrations of Praseodymium (element) in the plasma were below the limit of quantification (<0.14 ng/mL). These results indicated that when Praseodymium (III, IV) oxide was administered to mice at the concentration of 1000 mg/kg/day, a fraction of Praseodymium was absorbed in the plasma. There were no abnormal general conditions nor apparent suppression of the body weight gain.
Under the conditions of this study, the results indicated that when Praseodymium (III, IV) oxide was administered to mice at the concentration of 1000 mg/kg/day, a fraction of Praseodymium was absorbed in the plasma.
The results of this study are considered to provide validation to the results of the TGR study (OECD TG 488, Kasamoto, 2018) written up in section 7.6.2 of this dataset.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.